Navigation Links
Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
Date:8/30/2012

ALBANY, New York, August 30, 2012 /PRNewswire/ --

Twease.org - New Report Added in Biotechnology Reports Database Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics

Mabs" and molecular tests are among the growth industries of pharmaceuticals and diagnostics, but they may have competition long-term from an unexpected source. Epigenomics is a potential game-changer in the clinical therapeutics market and significant in testing as well. It refers to technologies involving changes in genetic material that find their origins in causes other than base pairs alterations in the DNA of the host. Examples of such changes include DNA methylation and histone acetylation, both of which have been known for many years to cause changes in gene expression. This report Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics describes the progress that has been made in our understanding of the basic science of epigenomics and considers the practical accomplishments being reported by the private sector.

To Browse Full Toc Visit: http://www.twease.org/report/epigenomics-present-and-future-applications-for-pharmaceuticals-and-diagnostics.htm

Epigenomics constitutes a challenge to the long held paradigm of DNA base pair sequences as the prime determinant of the phenotype. Because of this profound intellectual shift, a vast new area of biological investigation is rapidly unfolding. This presents significant opportunities for understanding disease processes and developing the means of combating them.

Epigenomic Mechanisms Discussed in the report include:

  • DNA methylation
  • Histone Acetylation
  • Histone Phosphorylation
  • Methylation
  • Sumoylation
  • Histone "chaperones"
  • MicroRNAs (miRNAs)

The examination of many diseases in a completely new light means there exist a wealth of opportunities to develop new diagnostic and therapeutic approaches. At the same time it means that outdated concepts will have to be revised. This report looks at the science behind epigenomics and deals with opportunities for product development based on epigenetic technologies and the outlook for the future in this exciting area of pharmaceutical technologies. In doing so, the report provides:

Related Reports:

Global Biobanking Market

Bioinformatics Research Market in India

Global Biopharmaceuticals Market

Global Industrial Enzymes Market

Co-promotion and Co-marketing Partnering Terms & Agreements

Endpoints - Clinical Trials in Cardiovascular Disorders

  • Discussion of the Basic Science and Mechanisms Behind Epigenomics
  • Activities of Top Companies in the Market
  • Interviews with Researchers and Private Sector Leaders
  • Market Estimates for Current Epigenomic Drugs and Forecast to 2017
  • Market Estimates for Current Epigenomic Diagnostics and Comparison to Next Gen Cancer Diagnostics Market
  • Analyst Conclusions Regarding the Future Market for Epigenomics
  • Key Healthcare Segments Impacted by Epigenomics
  • Examples of Clinically Relevant Epigenetic Biomarkers
  • Currently Approved Epigenomic Drugs
  • Epigenetic Drivers of Disease
  • Pharmaceutical R&D: A Need for Better Returns
  • Look at Applications in Alzheimer's Disease, Mental Illness, Auto-Immune Diseases, Autism and Cardiovascular Disease

The report strives to predict the potential for epigenomics while reminding market-watchers of the challenges and possible limiting factors in this market. As the report states:

"In the examination of Google hits for "Epigenomics," the phrases "exciting", "state of the art", "cutting edge", "innovative", "breakthrough" and other clichés are encountered over and over. These terms are frequently employed to cover up ideas, concepts and scientific discoveries that may NOT be cutting edge or state of the art and may be past their time, or may never have reached their time. For this reason the report will consider which of these technologies have value and may be ripe for exploitation."

The study of epigenomics today finds itself at a tuningpoint, with many unanswered questions and a proliferation of opportunities forproducts based on the constant flow of new research findings. This report is essential for pharmaceutical and diagnostic marketers looking to develop future business plans and determine opportunities in a promising field.

Related Reports:

Assessment of the fast growing Indian Biotech Market

Genetic Testing Market

Biobanking: Applications - A Global Market

Pharmaceutical Pricing and Reimbursement - Adoption of Health Technology Assessments (HTA) Optimizes Drug Pricing and Accelerates Reimbursement Decision-Making

Inflammatory Bowel Disease Global Clinical Trials Review

About Us

Twease.org is the number one stop for all the latest reports, news and industry information related to pharmaceutical domain. Our database represents a collection which is updated on a daily basis and consists of all major pharmaceutical market research publishers.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
Email: sales@twease.org
Visit: http://www.twease.org/ 
Buy SWOT: http://www.wpt9.com/ 


'/>"/>
SOURCE Twease.org
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
5. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
6. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
7. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
8. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
9. PRA Expert to Present at Pharmacovigilance Conference
10. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
11. Verenium to Present at Baird Clean Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)...  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing ... that Linda Marbán, Ph.D, president and chief executive officer, is ... Cowen and Company 37th Annual Health Care Conference ... Boston, MA 29th Annual ROTH ... pm ET) Dana Point, CA ...
(Date:2/23/2017)... DIEGO and SAN FRANCISCO ... a privately-held regenerative medicine company, and Beyond Type 1, ... with type 1 diabetes, today announced a grant from ... a functional cure for type 1 and other insulin-requiring ... ViaCyte has been developing innovative stem cell-derived cell replacement ...
(Date:2/22/2017)...  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company ... products for companion animals, will host a live conference call ... discuss financial results from the fourth quarter and full year ... investors may access the audio webcast or use ... ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , a leader in Atomic ... all SPIE attendees and Park customers on Feb. 27, 2017 from 12-2pm ... Jose Convention Center. The luncheon will feature a talk on Automated AFM for ...
Breaking Biology Technology:
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... , its innovative, highly flexible and award winning ... customers. iMedNet is a proven Software-as-a-Service ... Electronic Data Capture (EDC), but also delivers an entire ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
Breaking Biology News(10 mins):